Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women

被引:134
作者
Azadbakht, Leila
Kimiagar, Masoud
Mehrabi, Yadollah
Esmaillzadeh, Ahmad
Padyab, Mojgan
Hu, Frank B.
Willett, Walter C.
机构
[1] Shahid Beheshti Univ Med Sci, Dept Human Nutr, Sch Nutr & Food Sci, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Tehran, Iran
[3] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
关键词
metabolic syndrome; insulin resistance; soy; glycemic control; lipid profiles;
D O I
10.1093/ajcn/85.3.735
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Little evidence exists regarding the effects of soy consumption on the metabolic syndrome in humans. Objective: We aimed to determine the effects of soy consumption on components of the metabolic syndrome, plasma lipids, lipoproteins, insulin resistance, and glycemic control in postmenopausal women with the metabolic syndrome. Design: This randomized crossover clinical trial was undertaken in 42 postmenopausal women with the metabolic syndrome. Participants were randomly assigned to consume a control diet (Dietary Approaches to Stop Hypertension, DASH), a soy-protein diet, or a soy-nut diet, each for 8 wk. Red meat in the DASH period was replaced by soy-protein in the soy-protein period and by soy-nut in the soy-nut period. Results: The soy-nut regimen decreased the homeostasis model of assessment-insulin resistance score significantly compared with the soy-protein (difference in percentage change: -7.4 +/- 0.8; P < 0.01) or control (-12.9 +/- 0.9; P < 0.01) diets. Consumption of soy-nut also reduced fasting plasma glucose more significantly than did the soy-protein (-5.3 +/- 0.5%; P < 0.01) or control (-5.1 +/- 0.6%; P < 0.01) diet. The soy-nut regimen decreased LDL cholesterol more than did the soy-protein period (-5.0 +/- 0.6%; P < 0.01) and the control (-9.5 0.6%; P < 0.01) diet. Soy-nut consumption significantly reduced serum C-peptide concentrations compared with control diet (-8.0 +/- 2.1; P < 0.01), but consumption of soy-protein did not. Conclusion: Short-term soy-nut consumption improved glycemic control and lipid profiles in postmenopausal women with the metabolic syndrome.
引用
收藏
页码:735 / 741
页数:7
相关论文
共 53 条
[1]   METAANALYSIS OF THE EFFECTS OF SOY PROTEIN-INTAKE ON SERUM-LIPIDS [J].
ANDERSON, JW ;
JOHNSTONE, BM ;
COOKNEWELL, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (05) :276-282
[2]  
ANDERSON JW, 1998, AM J CLIN NUTR S, V68
[3]   Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults [J].
Azadbakht, L ;
Mirmiran, P ;
Esmaillzadeh, A ;
Azizi, F .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2005, 82 (03) :523-530
[4]   Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome [J].
Azadbakht, L ;
Mirmiran, P ;
Esmaillzadeh, A ;
Azizi, T ;
Azizi, F .
DIABETES CARE, 2005, 28 (12) :2823-2831
[5]   Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy [J].
Azadbakht, L ;
Shakerhosseini, R ;
Atabak, S ;
Jamshidian, M ;
Mehrabi, Y ;
Esmaill-Zadeh, A .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2003, 57 (10) :1292-1294
[6]   Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study [J].
Azizi, F ;
Salehi, P ;
Etemadi, A ;
Zahedi-Asl, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 (01) :29-37
[7]  
BARNES S, 1995, J CELL BIOCHEM, P181
[8]  
BURSTEIN M, 1970, J LIPID RES, V11, P583
[9]   Prevalence and correlates of metabolic syndrome (MS) in older adults [J].
Cankurtaran, M ;
Halil, M ;
Yavuz, BB ;
Dagli, N ;
Oyan, B ;
Ariogul, S .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2006, 42 (01) :35-45
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497